NDLI: Effects of cholecalciferol on functional, biochemical, vascular, and quality of life outcomes in hemodialysis patients.

Content Provider	World Health Organization (WHO)-Global Index Medicus
Author	Hewitt, Nathan A. O'Connor, Alicia A. O'Shaughnessy, Denise V. Elder, Grahame J.
Spatial Coverage	New South Wales
Description	Country affiliation: Australia Author Affiliation: Hewitt NA ( Postgraduate Medical School, University of Notre Dame, Sydney, Australia.)
Abstract	BACKGROUND AND OBJECTIVES: Observational studies suggest that calciferol supplementation may improve laboratory and patient-level outcomes of hemodialysis patients with reduced 25-hydroxyvitamin D [25(OH)D] levels. This randomized controlled trial examined effects of cholecalciferol supplementation in patients on hemodialysis. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Sixty patients with 25(OH)D levels ≤24 ng/ml (≤60 nmol/L) were randomized to receive 50,000 IU oral cholecalciferol or placebo, once weekly for 8 weeks and then monthly for 4 months. At baseline (autumn 2011) and 6 months, testing evaluated muscle strength, functional capacity, laboratory parameters, pulse wave velocity (PWV), and health-related quality of life (HRQOL) using the Kidney Disease Quality of Life-36 survey. RESULTS: Patients were well matched by treatment allocation. Median age was 62 years (range, 20-86), 52% were women, 55% had a history of diabetes, and mean serum 25(OH)D was 17±5 ng/ml (43±13 nmol/L). Patients were assessed over 6 months by repeated-measures ANOVA. Patients allocated to cholecalciferol had significantly higher values of 25(OH)D (P<0.001), 1,25-dihydroxyvitamin D (P=0.04), and tartrate-resistant acid phosphatase-5b) (P=0.04) and a greater reduction in phosphorus values (P=0.03) than placebo-treated patients Values of serum calcium, intact parathyroid hormone, and episodes of hypercalcemia and hyperphosphatemia did not differ significantly between the groups. No significant differences were detected in muscle strength, functional capacity, PWV, or HRQOL. CONCLUSIONS: In this randomized controlled trial, patients supplemented with cholecalciferol had higher 25(OH)D, 1,25-dihydroxyvitamin D, and tartrate-resistant acid phosphatase-5b levels, without increased calcium or phosphorus values. However, no effects were detected in muscle strength, functional capacity, PWV, or HRQOL.
File Format	HTM / HTML
ISSN	15559041
e-ISSN	1555905X
DOI	10.2215/CJN.02840312
Journal	Clinical Journal of the American Society of Nephrology
Issue Number	7
Volume Number	8
Language	English
Publisher	American Society of Nephrology
Publisher Date	2013-07-01
Publisher Place	United States
Access Restriction	Open
Subject Keyword	Kidney Diseases Therapy Research Support, Non-u.s. Gov't New South Wales Pulse Wave Analysis Biological Markers Psychology Vitamin D Deficiency Double-blind Method Blood Quality Of Life Time Factors Vitamin D Questionnaires Diagnosis Vascular Stiffness Muscle Strength Cholecalciferol Drug Therapy Discipline Nephrology Randomized Controlled Trial Drug Effects Therapeutic Use Vitamins Physiopathology Biomechanical Phenomena Range Of Motion, Articular Analysis Of Variance Health Status Dietary Supplements Analogs & Derivatives Renal Dialysis
Content Type	Text
Resource Type	Article
Subject	Transplantation Critical Care and Intensive Care Medicine Nephrology Epidemiology

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

25-Hydroxyvitamin D response to cholecalciferol supplementation in hemodialysis.

Calcium absorption response to cholecalciferol supplementation in hemodialysis.

Why dialysis patients need combination therapy with both cholecalciferol and a calcitriol analogs.

Cholecalciferol supplementation in hemodialysis patients: effects on mineral metabolism, inflammation, and cardiac dimension parameters.

Nutritional vitamin D supplementation in dialysis: a randomized trial.

Impact of cholecalciferol treatment on biomarkers of inflammation and myocardial structure in hemodialysis patients without hyperparathyroidism.

Once-weekly dose of 8400 IU vitamin D(3) compared with placebo: effects on neuromuscular function and tolerability in older adults with vitamin D insufficiency.

Effect of cholecalciferol on local arterial stiffness and endothelial dysfunction in children with chronic kidney disease.

Vitamin D in dialysis: defining deficiency and rationale for supplementation.

Effects of cholecalciferol on functional, biochemical, vascular, and quality of life outcomes in hemodialysis patients.

Similar Documents

25-Hydroxyvitamin D response to cholecalciferol supplementation in hemodialysis.

Calcium absorption response to cholecalciferol supplementation in hemodialysis.

Why dialysis patients need combination therapy with both cholecalciferol and a calcitriol analogs.

Cholecalciferol supplementation in hemodialysis patients: effects on mineral metabolism, inflammation, and cardiac dimension parameters.

Nutritional vitamin D supplementation in dialysis: a randomized trial.

Impact of cholecalciferol treatment on biomarkers of inflammation and myocardial structure in hemodialysis patients without hyperparathyroidism.

Once-weekly dose of 8400 IU vitamin D(3) compared with placebo: effects on neuromuscular function and tolerability in older adults with vitamin D insufficiency.

Effect of cholecalciferol on local arterial stiffness and endothelial dysfunction in children with chronic kidney disease.

Vitamin D in dialysis: defining deficiency and rationale for supplementation.

Effects of cholecalciferol on functional, biochemical, vascular, and quality of life outcomes in hemodialysis patients.